Wells Fargo Downgrades Foundation Medicine to Market Perform | GenomeWeb

NEW YORK (GenomeWeb) – Wells Fargo's Equity Research Department today downgraded Foundation Medicine's stock to Market Perform from Outperform, following the company's first ever analyst day on Tuesday.

Wells Fargo also increased its 2016 estimated loss per share for Foundation Medicine to $1.36 from $1.29, and reduced its stock valuation range to $25 to $27 per share from a previous $35 to $40 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.